PT
Therapeutic Areas
Tectonic Therapeutic Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TX000045 (TX45) | Heart Failure with Preserved Ejection Fraction (HFpEF) / Group 2 Pulmonary Hypertension | Phase 1 |
| Relaxin Program | Group 2 Pulmonary Hypertension | Preclinical |
| Undisclosed Program | Hereditary Hemorrhagic Telangiectasia (HHT) | Discovery |
Leadership Team at Tectonic Therapeutic
AR
Alise Reicin
President and CEO, Director
JD
John Diener
Senior Vice President, Antibody Engineering & Protein Sciences
DL
Daniel Lochner
Chief Financial Officer
PM
Peter McNamara
Chief Scientific Officer
AM
Anthony Muslin
Chief Development Officer
MK
Marcella K Ruddy
Chief Medical Officer
MS
Marc Schwabish
Chief Business Officer
GP
Geraldine Peters-Wiles
Senior Vice President, Human Resources
BR
Barry Rubenstein
Senior Vice President, People & Culture
TA
Timothy A. Springer
Co-Founder, Board Director